Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
- Associated Conditions
- -
- Associated Therapies
- -
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 138
- Registration Number
- NCT06472739
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 62
- Registration Number
- NCT06450041
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT06013618
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 60
- Registration Number
- NCT05790447
- Locations
- 🇨🇳
The Second Affiliated Hospital of SchoowUniversity, Suzhou, China
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Xiangpan Li
- Target Recruit Count
- 56
- Registration Number
- NCT05760196
- Locations
- 🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 45
- Registration Number
- NCT05603013
- Locations
- 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, China
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 56
- Registration Number
- NCT05530200
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Epitopoietic Research Corporation
- Target Recruit Count
- 28
- Registration Number
- NCT05366062
- Locations
- 🇹🇭
Bumrungrad International Hospital, Bangkok, Vadhana, Thailand
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 40
- Registration Number
- NCT05307835
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-31
- Target Recruit Count
- 71
- Registration Number
- NCT05292417
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.